Genetic Deletion of a Single Immunodominant T-cell Response Confers Susceptibility to Virus-induced Demyelination

Overview

Journal Brain Pathol

Date 2007 Mar 29

PMID 17388949

Citations 13

Authors

Kevin D Pavelko

Larry R Pease

Chella S David

Moses Rodriguez

Affiliations

Soon will be listed here.

Abstract

An important question in neuropathology involves determining the antigens that are targeted during demyelinating disease. Viral infection of the central nervous system (CNS) leads to T-cell responses that can be protective as well as pathogenic. In the Theiler's murine encephalomyelitis virus (TMEV) model of demyelination it is known that the immune response to the viral capsid protein 2 (VP2) is critical for disease pathogenesis. This study shows that expressing the whole viral capsid VP2 or the minimal CD8-specific peptide VP2(121-130) as "self" leads to a loss of VP2-specific immune responses. Loss of responsiveness is caused by T cell-specific tolerance, as VP2-specific antibodies are generated in response to infection. More importantly, these mice lose the CD8 T-cell response to the immunodominant peptide VP2(121-130), which is critical for the development of demyelinating disease. The transgenic mice fail to clear the infection and develop chronic demyelinating disease in the spinal cord white matter. These findings demonstrate that T-cell responses can be removed by transgenic expression and that lack of responsiveness alters viral clearance and CNS pathology. This model will be important for understanding the mechanisms involved in antigen-specific T-cell deletion and the contribution of this response to CNS pathology.

Citing Articles

Brain atrophy in picornavirus-infected FVB mice is dependent on the H-2D class I molecule.

Huseby Kelcher A, Atanga P, Gamez J, Cumba Garcia L, Teclaw S, Pavelko K FASEB J. 2017; 31(6):2267-2275.

PMID: 28188174 PMC: 5434653. DOI: 10.1096/fj.201601055R.

LincRNA-Cox2 Promotes Late Inflammatory Gene Transcription in Macrophages through Modulating SWI/SNF-Mediated Chromatin Remodeling.

Hu G, Gong A, Wang Y, Ma S, Chen X, Chen J J Immunol. 2016; 196(6):2799-2808.

PMID: 26880762 PMC: 4779692. DOI: 10.4049/jimmunol.1502146.

Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity.

Painter M, Morrison J, Zoecklein L, Rinkoski T, Watzlawik J, Papke L PLoS Pathog. 2015; 11(12):e1005311.

PMID: 26633895 PMC: 4669089. DOI: 10.1371/journal.ppat.1005311.

Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis.

Denic A, Wootla B, Zoecklein L, Rodriguez M J Neurol Transl Neurosci. 2014; 2(1).

PMID: 25383388 PMC: 4222056.

Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Panos M, Christophi G, Rodriguez M, Scarisbrick I Biol Chem. 2014; 395(9):1063-73.

PMID: 25153387 PMC: 4144048. DOI: 10.1515/hsz-2014-0141.

References

Schorpp M, Jager R, Schellander K, Schenkel J, Wagner E, Weiher H . The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Nucleic Acids Res. 1996; 24(9):1787-8. PMC: 145851. DOI: 10.1093/nar/24.9.1787. View

Njenga M, Pavelko K, Baisch J, Lin X, David C, Leibowitz J . Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. J Virol. 1996; 70(3):1729-37. PMC: 189997. DOI: 10.1128/JVI.70.3.1729-1737.1996. View

Borson N, Paul C, Lin X, Nevala W, Strausbauch M, Rodriguez M . Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue. J Virol. 1997; 71(7):5244-50. PMC: 191760. DOI: 10.1128/JVI.71.7.5244-5250.1997. View

Miller S, Vanderlugt C, Begolka W, Pao W, Yauch R, Neville K . Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med. 1997; 3(10):1133-6. DOI: 10.1038/nm1097-1133. View

Yauch R, Palma J, Yahikozawa H, Koh C, Kim B . Role of individual T-cell epitopes of Theiler's virus in the pathogenesis of demyelination correlates with the ability to induce a Th1 response. J Virol. 1998; 72(7):6169-74. PMC: 110426. DOI: 10.1128/JVI.72.7.6169-6174.1998. View

Murray P, Pavelko K, Leibowitz J, Lin X, Rodriguez M . CD4(+) and CD8(+) T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. J Virol. 1998; 72(9):7320-9. PMC: 109956. DOI: 10.1128/JVI.72.9.7320-7329.1998. View

Szomolanyi-Tsuda E, Welsh R . T-cell-independent antiviral antibody responses. Curr Opin Immunol. 1998; 10(4):431-5. DOI: 10.1016/s0952-7915(98)80117-9. View

Drescher K, Murray P, David C, Pease L, Rodriguez M . CNS cell populations are protected from virus-induced pathology by distinct arms of the immune system. Brain Pathol. 1999; 9(1):21-31. PMC: 8098348. DOI: 10.1111/j.1750-3639.1999.tb00206.x. View

Johnson A, Njenga M, Hansen M, Kuhns S, Chen L, Rodriguez M . Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. J Virol. 1999; 73(5):3702-8. PMC: 104145. DOI: 10.1128/JVI.73.5.3702-3708.1999. View

10.

Baldwin T, Hogquist K, Jameson S . The fourth way? Harnessing aggressive tendencies in the thymus. J Immunol. 2004; 173(11):6515-20. DOI: 10.4049/jimmunol.173.11.6515. View

11.

Kang B, Kang H, Kim B . Identification of capsid epitopes of Theiler's virus recognized by CNS-infiltrating CD4+ T cells from virus-infected C57BL/6 mice. Virus Res. 2005; 108(1-2):57-61. DOI: 10.1016/j.virusres.2004.08.001. View

12.

Disis M, Salazar L, Knutson K . Peptide-based vaccines in breast cancer. Breast Dis. 2005; 20:3-11. DOI: 10.3233/bd-2004-20102. View

13.

Lohr J, Knoechel B, Nagabhushanam V, Abbas A . T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol Rev. 2005; 204:116-27. DOI: 10.1111/j.0105-2896.2005.00241.x. View

14.

Johnson A, Mendez-Fernandez Y, Moyer A, Sloma C, Pirko I, Block M . Antigen-specific CD8+ T cells mediate a peptide-induced fatal syndrome. J Immunol. 2005; 174(11):6854-62. DOI: 10.4049/jimmunol.174.11.6854. View

15.

Verhoef A, Alexander C, Kay A, Larche M . T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. 2005; 2(3):e78. PMC: 1069669. DOI: 10.1371/journal.pmed.0020078. View

16.

Hogquist K, Baldwin T, Jameson S . Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005; 5(10):772-82. DOI: 10.1038/nri1707. View

17.

Tsunoda I, Kuang L, Kobayashi-Warren M, Fujinami R . Central nervous system pathology caused by autoreactive CD8+ T-cell clones following virus infection. J Virol. 2005; 79(23):14640-6. PMC: 1287580. DOI: 10.1128/JVI.79.23.14640-14646.2005. View

18.

Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G . Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000; 6(10):1167-75. DOI: 10.1038/80516. View

19.

Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P . Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study.... Nat Med. 2000; 6(10):1176-82. DOI: 10.1038/80525. View

20.

Walker L, Abbas A . The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002; 2(1):11-9. DOI: 10.1038/nri701. View